Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation

Makoto Nakamura, Nobuharu Fujii, Kazuyoshi Shimizu, Shuntaro Ikegawa, Keisuke Seike, Tomoko Inomata, Yasuhisa Sando, Keiko Fujii, Hisakazu Nishimori, Ken ichi Matsuoka, Hiroshi Morimatsu, Yoshinobu Maeda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited. Most previous studies have evaluated short-term outcomes using ICU mortality; there have been comparatively fewer reports of long-term outcomes. We retrospectively analyzed 39 HSCT patients admitted to the ICU for the first time between April 2008 and July 2014. Performance status was evaluated in four long-term survivors in July 2016. Median age at ICU admission was 54 years (range 30–68). In total, 33 patients (70.2%) required mechanical ventilation and 31 patients (66%) required dialysis. The median OS from first ICU admission was 41 days (95% confidence interval [CI]: 22–64) and the 1-year survival rate was 12.8% (95% CI 4.7–25.2). No statistically significant factors were associated with short-term outcomes. Among long-term outcomes, a second or subsequent HSCT and neutropenia at ICU admission were significant risk factors. Four of 10 ICU survivors have survived with good performance status for a median of 1994 (1203–2633) days. Our results suggest that the number of prior transplants and neutropenia at ICU admission may influence OS.

Original languageEnglish
Pages (from-to)622-629
Number of pages8
JournalInternational journal of hematology
Volume108
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Keywords

  • Hematopoietic stem cell transplantation
  • Intensive care unit
  • Long-term outcomes
  • Neutropenia
  • Number of prior transplants

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this